Skip to main content

Impact of APOE in mild cognitive impairment.

Publication ,  Journal Article
Farlow, MR; He, Y; Tekin, S; Xu, J; Lane, R; Charles, HC
Published in: Neurology
November 23, 2004

OBJECTIVE: The authors aimed to use baseline data of an ongoing large, prospective study in subjects with mild cognitive impairment (MCI) to investigate the impact of APOE genotype on the symptom profile of the condition. METHODS: Cognitive assessments included the AD Assessment Scale cognitive subscale (ADAS-cog), the Mini-Mental State Examination (MMSE), and a cognitive battery for assessment of memory, attention, and executive function. Behavioral assessments included the Neuropsychiatric Inventory and Beck Depression Inventory. Activities of daily living were assessed by the AD Cooperative Study Activities of Daily Living (ADCS-ADL) scale. Hippocampal volumes were measured with MRI. RESULTS: A total of 494 of 1,018 study subjects provided APOE data. Approximately 40% of the subjects were APOE epsilon4 carriers. APOE epsilon4 carriers had lower MMSE (p = 0.01) and higher ADAS-cog (p < 0.0001) scores than noncarriers, indicating worse cognitive impairment. APOE epsilon4 carriers also had greater deficits on New York University delayed paragraph recall and Buschke free and cued selective reminding tests, and on the ADCS-ADL scale (p < 0.001). They also had smaller hippocampal volumes (p = 0.002). Behavioral scores were similar across the subgroups. CONCLUSION: MCI subjects carrying the APOE epsilon4 allele showed distinct cognitive and imaging profiles, which appeared to resemble those of early Alzheimer patients. APOE epsilon4 genotype was associated with greater impairments in memory and functional activities as well as hippocampal atrophy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Neurology

DOI

EISSN

1526-632X

Publication Date

November 23, 2004

Volume

63

Issue

10

Start / End Page

1898 / 1901

Location

United States

Related Subject Headings

  • Rivastigmine
  • Randomized Controlled Trials as Topic
  • Phenylcarbamates
  • Nootropic Agents
  • Neuropsychological Tests
  • Neurology & Neurosurgery
  • Middle Aged
  • Male
  • Magnetic Resonance Imaging
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Farlow, M. R., He, Y., Tekin, S., Xu, J., Lane, R., & Charles, H. C. (2004). Impact of APOE in mild cognitive impairment. Neurology, 63(10), 1898–1901. https://doi.org/10.1212/01.wnl.0000144279.21502.b7
Farlow, M. R., Y. He, S. Tekin, J. Xu, R. Lane, and H. C. Charles. “Impact of APOE in mild cognitive impairment.Neurology 63, no. 10 (November 23, 2004): 1898–1901. https://doi.org/10.1212/01.wnl.0000144279.21502.b7.
Farlow MR, He Y, Tekin S, Xu J, Lane R, Charles HC. Impact of APOE in mild cognitive impairment. Neurology. 2004 Nov 23;63(10):1898–901.
Farlow, M. R., et al. “Impact of APOE in mild cognitive impairment.Neurology, vol. 63, no. 10, Nov. 2004, pp. 1898–901. Pubmed, doi:10.1212/01.wnl.0000144279.21502.b7.
Farlow MR, He Y, Tekin S, Xu J, Lane R, Charles HC. Impact of APOE in mild cognitive impairment. Neurology. 2004 Nov 23;63(10):1898–1901.

Published In

Neurology

DOI

EISSN

1526-632X

Publication Date

November 23, 2004

Volume

63

Issue

10

Start / End Page

1898 / 1901

Location

United States

Related Subject Headings

  • Rivastigmine
  • Randomized Controlled Trials as Topic
  • Phenylcarbamates
  • Nootropic Agents
  • Neuropsychological Tests
  • Neurology & Neurosurgery
  • Middle Aged
  • Male
  • Magnetic Resonance Imaging
  • Humans